Published in final edited form as:

J Am Acad Dermatol. 2008 November ; 59(5): 881–886. doi:10.1016/j.jaad.2008.06.030.

Skin cancers, blindness and anterior tongue mass in African brothers

Priya Mahindra, BA^{a,b}, John J. DiGiovanna, MD^{b,c}, Deborah Tamura, RN, MS^a, Jaime S. Brahim, DDS, MS^d, Thomas J. Hornyak, MD, PhD^e, Jere B. Stern, MD^f, Chyi-Chia Richard Lee, MD, PhD^f, Sikandar G. Khan, PhD^a, Brian P. Brooks, MD, PhD^g, Janine A. Smith, MD^g, Brian P. Driscoll, MD^h, Andrew D. Montemarano, D.O.ⁱ, Kate Sugarman, MD^j, and Kenneth H. Kraemer, MD^a

^aBasic Research Laboratory, DNA Repair Section, Center for Cancer Research, National Cancer Institute

^bClinical Research Training Program, National Institutes of Health

^cDermatopharmacology Division, Department of Dermatology, The Warren Alpert School of Medicine at Brown University

^dNational Institute of Dental and Craniofacial Research

^eDermatology Branch, Center for Cancer Research, National Cancer Institute

^fLaboratory of Pathology, Center for Cancer Research, National Cancer Institute

^gNational Eye Institute

^hNational Institute of Deafness and other Communication Disorders

ⁱSkin Cancer Surgery Center, Bethesda, MD

^jCommunity of Hope Health Services, Washington, DC

Keywords

xeroderma pigmentosum; DNA repair; skin cancer; dermoscopy; tongue cancer; ultraviolet damage; black skin; eye damage

© 2008 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Contact: Kenneth H. Kraemer, M.D., Chief, DNA Repair Section, Basic Research Laboratory, Center for Cancer Research, National Cancer Institute, Building 37 Room 4002 MSC 4258, Bethesda, MD 20892 -4258, 301-496-9033 FAX: 301-594-3409, e-mail: E-mail: kraemer@nih.gov.

Editor's note: Dr. Kraemer is an authority on DNA repair deficiency diseases, including XP, trichothiodystrophy, and Cockayne syndrome. Clinicians can refer interested patients to the NIH patient recruitment and referral office at 800-411-1222 or by e-mail at kraemer@nih.gov. XP support groups include the XP Society (<http://www.xps.org>); the XP Family Support Group <http://www.xpfamilysupport.org/>; the Xeroderma Pigmentosum Support Group (United Kingdom) (<http://xpsupportgroup.org.uk>); Enfants de la lune (France) (<http://asso.orpha.net/AXP/>); and XP-Freu(n)de (Germany) <http://www.xerodermapigmentosum.de/>

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Case Summary

History

Two Northern African brothers presented to the NIH for evaluation of severe damage to sun exposed areas of the skin, eyes and mucosa; multiple skin cancers; a tongue mass; and photophobia with loss of vision.

The patients were born full term after uncomplicated pregnancies and achieved age appropriate developmental milestones. Patient XP393BE, (Figure 1A) 23 years old, was noted to have freckle-like pigmented lesions on his face at 2.5 years and photophobia by age 3 (Table 1). A squamous cell carcinoma (SCC) was removed from his nose at age 13 and the site was grafted with sun shielded skin from his thigh. His brother, Patient XP394BE (Figure 1D), 17 years old, developed freckle-like lesions on his face by 8 years of age. At age 13 a SCC was excised from his right cheek. Both boys had bilateral progressive loss of vision with unilateral blindness since age 12–14 years (Fig 1B).

Patient XP393BE had a 10 year history of a slowly enlarging, painful, bleeding mass on the tip of his tongue (Figure 2A). He denied weight loss, excessive consumption of alcohol or chewing of tobacco or betel quid.

Living in Kuwait, Sudan, Libya and Egypt neither patient had a history of sunburns or use of sun protection. The patients have a 21 year old unaffected brother. Their parents were second cousins and members of the same tribe in the Sudan. There was no family history of cancer.

Physical Examination

Skin examination of both patients revealed numerous 1–5 mm hyperpigmented macules on the cheeks and scalp (Figure 1 and Figure 2) and sun exposed portions of the chest and extremities with sparing of sun protected sites. Patient XP393BE had a 1.3×1.7 cm stellate, indurated, black, brown and gray plaque on his left cheek (Figure 1A). Dermoscopy revealed characteristic leaf-like structures and blue-grey ovoid nests that distinguish pigmented BCC from melanoma (Fig 1C). A 1 cm nodular, ulcerated mass was present on the base of his nose and there were multiple pearly black lesions on his face. Patient XP394BE had a crusted darkly pigmented plaque on the left ala and tip of the nose (Fig 1D). Ocular examination of both patients revealed increased freckle-like pigmentation of the lids, conjunctival injection, and corneal scarring with neovascularization which occluded vision. Patient XP393BE's left eye had pigmented areas on the bulbar and palpebral conjunctiva, a left lateral pterygium, and an ectropion with keratinization of the lower lid (Figure 1B). Patient XP394BE had blepharitis, ptosis, and prominent vessels on his right eye. The lips of Patient XP393BE had mild cheilitis, loss of vermillion border, and hyperpigmented macules (Figure 2A). Oral examination revealed an ulcerated 1.5×3 cm fungating mass on the left anterior tip of his tongue and (Figure 2A) he had a bleeding pedunculated mass in his right nostril. Neither brother had cervical, axillary or inguinal lymphadenopathy. Their neurological examinations were normal.

Diagnostic Studies and Treatment

Patient XP393BE had iron deficiency anemia (HGB 10.1 g/dL [NI:12.7–16.7], HCT 31.5% [NI: 36.7–48.3], serum iron: 35 mcg/dL [NI: 50–150]; transferrin: 384 mg/dL [NI: 204–345]; 6% saturation [NI: 15–62%]; ferritin: 6 mcg/dL [NI: 18–370]). Both patients were vitamin D deficient (25-OH-Vit D 9–10 ng/ml [< 10 severe deficiency]). Computed tomography of the head, neck and posterior thoracic inlet were negative for metastasis for both brothers. Panorex radiography revealed that Patient XP393BE had a 2.5 cm multi-locular lesion with radiolucent and radio-opaque areas on the right mandible containing an inverted displaced tooth #32.

Sequencing of DNA from both patients revealed a homozygous two nucleotide deletion [c. 1643_1644delTG, p.Val548Alafs*25] in exon 9 of the *XPC* gene [NM_004628.3].

Biopsies of the facial lesions showed 10 pigmented BCC in Patient XP393BE and 2 pigmented BCC in patient XP394BE (Figure 1). The pedunculated tongue mass of Patient XP393BE (Figure 2A) was excised at the stalk followed by a wedge shaped excision of the base of the lesion. Histologic examination of the resected tongue mass revealed a central core of inflamed granulation tissue, surfaced by a layer of focally ulcerated, severely dysplastic squamous mucosal epithelium. Histopathological examination of the wedge shaped excision specimen at the base of the lesion revealed a well-differentiated, superficially invasive SCC (Figure 2B) arising in a background of moderately to severely dysplastic squamous mucosal epithelium., The surrounding area of dysplasia was treated with CO₂-laser ablation. Biopsy of the bleeding mass in the right nasal septum of Patient XP393BE was consistent with pyogenic granuloma. The lesion of the right mandible was enucleated and histology of the resected lining showed a keratocystic odontogenic tumor.

Diagnosis: Xeroderma pigmentosum (XP)

Follow-up

The brothers were instructed to avoid sun exposure and to practice rigorous sun protection. The skin cancers in both brothers will be treated with excision and Mohs surgery. The tongue and mandible of Patient XP393BE healed well. His anemia resolved on iron supplementation. The area of his right mandible will be followed periodically due to the potentially high recurrence of keratocystic odontogenic tumors¹. The vitamin D deficiency in both patients resolved with oral vitamin supplementation.

Discussion

XP is a rare, autosomal recessive inherited disease characterized by increased susceptibility to cancer of sun exposed mucocutaneous and ocular structures due to defective repair of ultraviolet (UV)-induced DNA damage.²⁻⁴ XP patients develop skin cancers at a mean age of less than 10 years^{5, 6}, a 50 year reduction in age of onset compared to the U.S. general population. Sunlight induced malignancies in XP patients occur at a 1000 fold greater frequency than in the general population. XP is present world-wide and has a prevalence of about 1:1,000,000 in the U.S and Europe⁷. It is more common in countries with high levels of consanguinity, including Japan⁸, Northern Africa and the Middle East. There is no race predilection.

Important clinical features of XP are cutaneous photosensitivity, xerosis, poikiloderma, actinic keratosis, and malignant lesions in sun exposed areas, including BCC, SCC, and melanoma. Approximately 50% of XP patients report a history of acute burning on minimal sun exposure⁵. The other half tan easily instead of burning, as did the patients in this report. The development of increased freckle-like pigmentation occurs in all XP patients following sun exposure and may occur before two years of age^{2,9}.

Ocular abnormalities in XP are limited to the anterior, UV absorbing, surfaces of the eyes and adnexa. They include photophobia, conjunctivitis, inflammatory masses and keratopathy that can progress to corneal opacification, and ocular neoplasms. Atrophy of the skin of the lids results in ectropion, entropion, or complete destruction of the lids^{2, 9,10}.

Approximately 30% of XP patients have progressive neurodegeneration⁵. The earliest manifestations of XP neurological disease may be diminished or absent deep tendon reflexes and high frequency hearing loss. Intellectual impairment and loss of motor control can occur

in later stages. MRI studies may reveal cerebral and cerebellar atrophy and enlarged ventricles². The primary histological finding is neuronal degeneration without inflammation or abnormal depositions^{2, 11}.

The clinical manifestations of XP are determined by a combination of both environmental and genetic factors. Skin, mucous membrane and ocular involvement is strongly linked to environmental sun exposure. Severity of skin disease is greatest on portions of the body exposed to the most amount of sunlight.⁵ The DNA nucleotide excision repair (NER) system plays a major role in prevention of cutaneous neoplasia. XP patients have cellular hypersensitivity to UV radiation secondary to faulty DNA NER^{3, 4, 12}. To date, there are 8 genes associated with clinical disease, *XPA*, *XPB*, *XPC*, *XPD*, *XPE*, *XPF*, *XPG*, (with defective NER) and XP variant (XP-V) (with defective DNA polymerase eta that bypasses DNA photoproducts). Mutations in *XPA*, *XPC*, *XPD* and polymerase eta account for more than 90% of XP¹³. Functional assays may be used for laboratory diagnosis of XP.³

Consistent with the history of parental consanguinity, the patients presented in this report were homozygous for a mutation in the *XPC* gene. This TG deletion frameshift mutation is predicted to result in premature termination of the encoded protein 25 amino acids downstream. The mutation might be a founder mutation since it was reported in other Northern African XP patients (Algeria and Morocco)¹⁴. It might also be a mutation hotspot in the *XPC* gene since it occurs in a run of 3 TG's and was reported in patients in different parts of the world (Italy, Honduras, and U.S.)^{14–16}.

These two brothers with similar genetic make-up and environmental exposure have similar clinical features of XP. They were not sun protected and had substantial exposure to UV due to their environment in Northern Africa. Dark skinned individuals have a lower incidence of skin cancer than the general population due, in part, to the photoprotective effects of melanin^{17, 18}. However, these XP patients sustained photodamage on their skin and non-melanin containing structures- the tip of the tongue and the anterior surface of the eyes. This demonstrates the importance of a normally functioning DNA repair system in protection against skin cancer even in darkly pigmented individuals⁵.

Carcinoma of the tip of the tongue has been reported in XP patients including patients of African and Middle Eastern descent^{5, 6, 9, 19, 20}, representing a 3000-fold increase in tongue tumors over the general population⁶. In the general population, tongue cancer is associated with excessive alcohol consumption, or tobacco, betel quid, or vinyl plastic wire chewing. The location is generally on the posterior, lateral tongue and the disease course is aggressive, requiring extensive treatment, and usually results in metastasis and early death²¹. The 5 year relative survival rate in 1996–2003 for black men with tongue cancer was only 34% [<http://seer.cancer.gov/statfacts/html/tongue.html>]. In XP patients, severe cheilitis of the lips and precancerous lesions such as leukoplakia may precede carcinoma of the tongue. Sun exposure may result from licking of the lips. Early age of occurrence, risk factors (UV exposure), location at the tip of the tongue and indolent course differentiate the oral carcinomas associated with XP from their homologues in adults in the general population. The mass on the anterior tip of the tongue of patient XP393BE was reported to be slowly growing and was predominantly comprised of inflamed granulation tissue. In view of the slow growth and minimal invasiveness of the SCC, we elected to treat the tongue tumor conservatively. After excising the base of the lesion, we used a CO₂ laser, which produces infrared radiation, for treatment of the surrounding dysplasia. In treating XP patients it is important to avoid using UV-emitting modalities, such as UV lamps, lasers or light-curing units, which could pose risk of further damage.

Education and sun protection are important in the management of XP. Early diagnosis and extensive sun protection have the potential to prevent skin cancers in XP patients and prolong their life expectancy^{2, 3, 22, 23}. Sun protection can be achieved by wearing protective clothing, UV-absorbing sunglasses with side shields and using topical sunblocking agents. UV absorbing films and filters can be placed over windows and fluorescent or halogen lamps. Thorough dermatologic examinations (including skin self examinations) to monitor any skin changes and ensure early detection and treatment of skin cancers should be performed regularly. Active XP patients who practice sun protection and maintain a good diet may have adequate vitamin D levels²⁴. However, XP patients who are protected from UV early in life may be at risk for vitamin D deficiency. Normal vitamin D levels can be maintained by oral vitamin D supplements. Genetic counseling is also an important component of patient management for this inherited disease, especially if a family has an affected child and is considering additional children³. Information about the availability of genetic testing for XP can be found at <http://genetests.org>. XP patient support groups are a valuable resource for educational and support services.

Key Teaching Points

- XP is an autosomal recessive inherited disease seen in all races throughout the world.
- Patients with XP have defective repair of UV-induced DNA damage resulting in markedly increased susceptibility to cancer of sun-exposed skin and mucus membranes, including the eyes and tip of the tongue. Defects in at least 8 different genes have been identified in XP patients.
- The diagnosis of XP can be made based on clinical features. While some patients may be exquisitely sun sensitive and experience severe sunburn after minimal sun exposure, others do not. All patients develop freckle-like pigmented lesions at an early age with poikilodermatous changes.
- Early diagnosis of XP and rigorous sun protection are important for prevention of cancer.

Abbreviations

BCC, basal cell carcinoma; CT, computed tomography; NER, nucleotide excision repair; NIH, National Institutes of Health; SCC, squamous cell carcinoma; UV, ultraviolet radiation; XP, xeroderma pigmentosum.

ACKNOWLEDGMENTS

Funding Sources: This research was supported by the Intramural Research Programs of the Center for Cancer Research, National Cancer Institute, of the National Institute of Dental and Craniofacial Research, of the National Eye Institute and of the National Institute of Deafness and other Communication Disorders of the NIH. Support for P.M. was made possible through the Clinical Research Training Program, a public-private partnership supported jointly by the NIH and Pfizer Inc (via a grant to the Foundation for NIH from Pfizer Inc). We thank Mary King and John Crawford, NIH Clinical Center patient photographers, for their excellent images.

Reference List

1. Madras J, Lapointe H. Keratocystic odontogenic tumour: reclassification of the odontogenic keratocyst from cyst to tumour. *J Can Dent Assoc* 2008;74:165–165h. [PubMed: 18353202]
2. Kraemer KH, Patronas NJ, Schiffmann R, Brooks BP, Tamura D, DiGiovanna JJ. Xeroderma pigmentosum, trichothiodystrophy and Cockayne syndrome: A complex genotype-phenotype relationship. *Neuroscience* 2007;145:1388–1396. [PubMed: 17276014]

3. Kraemer, KH.; Ruenger, TM. Genome instability, DNA repair and cancer. In: Wolff, K.; Goldsmith, LA.; Katz, SI.; Gilchrist, BA.; Paller, AS.; Leffell, DJ., editors. *Fitzpatrick's Dermatology in General Medicine*. Vol. 7 ed.. New York: McGraw Hill; 2008. p. 977-986.
4. Ruenger, TM.; DiGiovanna, JJ.; Kraemer, KH. Hereditary Diseases of genome instability and DNA repair. In: Wolff, K.; Goldsmith, LA.; Katz, SI.; Gilchrist, BA.; Paller, AS.; Leffell, DJ., editors. *Fitzpatrick's Dermatology in General Medicine*. Vol. 7 ed.. New York: McGraw Hill; 2008. p. 1311-1325.
5. Kraemer KH, Lee MM, Scotto J. Xeroderma pigmentosum. Cutaneous, ocular, and neurologic abnormalities in 830 published cases. *Arch Dermatol* 1987;123:241–250. [PubMed: 3545087]
6. Kraemer KH, Lee M-M, Andrews AD, Lambert WC. The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer: The xeroderma pigmentosum paradigm. *Arch Dermatol* 1994;130:1018–1021. [PubMed: 8053698]
7. Kleijer WJ, Laugel V, Berneburg M, Nardo T, Fawcett H, Gratchev A, et al. Incidence of DNA repair deficiency disorders in western Europe: Xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy. *DNA Repair (Amst)*. 2008
8. Hirai Y, Kodama Y, Moriwaki S, Noda A, Cullings HM, MacPhee DG, et al. Heterozygous individuals bearing a founder mutation in the XPA DNA repair gene comprise nearly 1% of the Japanese population. *Mutat Res* 2006;601:171–178. [PubMed: 16905156]
9. Goyal JL, Rao VA, Srinivasan R, Agrawal K. Oculocutaneous manifestations in xeroderma pigmentosa. *Br J Ophthalmol* 1994;78:295–297. [PubMed: 8199117]
10. Dollfus H, Porto F, Caussade P, Speeg-Schatz C, Sahel J, Grosshans E, et al. Ocular manifestations in the inherited DNA repair disorders. *Surv Ophthalmol* 2003;48:107–122. [PubMed: 12559331]
11. Rapin I, Lindenbaum Y, Dickson DW, Kraemer KH, Robbins JH. Cockayne syndrome and xeroderma pigmentosum. *Neurology* 2000;55:1442–1449. [PubMed: 11185579]
12. Friedberg, EC.; Walker, GC.; Siede, W.; Wood, RD.; Schultz, RA.; Ellenberger, T. Vol. 2 ed.. Washington, D.C: ASM Press; 2006. *DNA Repair and Mutagenesis*.
13. Moriwaki S, Kraemer KH. Xeroderma pigmentosum--bridging a gap between clinic and laboratory. *Photodermatol Photoimmunol Photomed* 2001;17:47–54. [PubMed: 11338401]
14. Khan SG, Oh KS, Shahnavi T, Ueda T, Busch DB, Inui H, et al. Reduced XPC DNA repair gene mRNA levels in clinically normal parents of xeroderma pigmentosum patients. *Carcinogenesis* 2006;27:84–94. [PubMed: 16081512]
15. Chavanne F, Broughton BC, Pietra D, Nardo T, Browitt A, Lehmann AR, et al. Mutations in the XPC gene in families with xeroderma pigmentosum and consequences at the cell, protein, and transcript levels. *Cancer Res* 2000;60:1974–1982. [PubMed: 10766188]
16. Li L, Bales ES, Peterson CA, Legerski RJ. Characterization of molecular defects in xeroderma pigmentosum group C. *Nature Genet* 1993;5:413–417. [PubMed: 8298653]
17. Tadokoro T, Kobayashi N, Zmudzka BZ, Ito S, Wakamatsu K, Yamaguchi Y, et al. UV-induced DNA damage and melanin content in human skin differing in racial/ethnic origin. *FASEB J* 2003;17:1177–1179. [PubMed: 12692083]
18. Yamaguchi Y, Takahashi K, Zmudzka BZ, Kornhauser A, Miller SA, Tadokoro T, et al. Human skin responses to UV radiation: pigment in the upper epidermis protects against DNA damage in the lower epidermis and facilitates apoptosis. *FASEB J* 2006;20:1486–1488. [PubMed: 16793869]
19. Khatri ML, Bemghazil M, Shafi M, Machina A. Xeroderma pigmentosum in Libya. *Int J Dermatol* 1999;38:520–524. [PubMed: 10440281]
20. Kraemer KH, Lee MM, Scotto J. DNA repair protects against cutaneous and internal neoplasia: evidence from xeroderma pigmentosum. *Carcinogenesis* 1984;5:511–514. [PubMed: 6705149]
21. Myers JN, Elkins T, Roberts D, Byers RM. Squamous cell carcinoma of the tongue in young adults: increasing incidence and factors that predict treatment outcomes. *Otolaryngol Head Neck Surg* 2000;122:44–51. [PubMed: 10629481]
22. Cox SE, Roberts LJ, Bergstresser PR. Prevention of skin cancer in xeroderma pigmentosum: The physician as advocate. *J Am Acad Dermatol* 1993;29:1045–1046. [PubMed: 8245244]
23. Slor H, Batko S, Khan SG, Sobe T, Emmert S, Khadavi A, et al. Clinical, Cellular, and Molecular Features of an Israeli Xeroderma Pigmentosum Family with a Frameshift Mutation in the XPC Gene: Sun Protection Prolongs Life. *J Invest Dermatol* 2000;115:974–980. [PubMed: 11121128]

24. Sollitto RB, Kraemer KH, DiGiovanna JJ. Normal vitamin D levels can be maintained despite rigorous photoprotection: Six years' experience with xeroderma pigmentosum. *J Am Acad Dermatol* 1997;37:942–947. [PubMed: 9418761]

Fig 1. Northern African brothers with xeroderma pigmentosum

A, Patient XP393BE, 23 years old, with multiple hyperpigmented macules and papules on photodistributed areas of face and neck. Nodular BCC (*arrow*) on the left base of nose. Pigmented BCC on left cheek (*rectangle*). B, UV induced ocular damage in Patient XP393BE, showing left eye ectropion (*arrow*), and conjunctival pterygium (*asterisk*). C, Dermoscopy of pigmented lesion on left lateral cheek of patient XP393BE (*rectangle* in A) reveals characteristic leaf-like structures and blue-grey ovoid nests that distinguish pigmented BCC from melanoma. D. Patient XP394BE, 17 y/o, with similar features to his brother including pigmented BCC on the left ala and severe eye involvement.

Fig 2. Squamous cell carcinoma tongue of patient XP393BE

A. Ulcerated 1×3 cm fungating mass on the left anterior tip of the tongue. Note the loss of vermillion border of the lips with cheilitis and marked freckle-like pigmentation. **B.** Histologic examination reveals a well-differentiated, keratinizing, superficially invasive SCC at the base of the pedunculated lesion, characterized by prominent cytologic atypia of lesional keratinocytes showing infiltrative growth pattern. A dense inflammatory infiltrate comprised predominantly of lymphocytes is also present. (Hematoxylin-eosin stain; original magnification: 200x.)

Table 1
Clinical features of Northern African brothers with XP

	Patient XP393BE	Patient XP394BE
Age	23 yr	17 yr
Skin and mucous membranes		
Acute photosensitivity upon minimal sun exposure	No	No
Hypo- and hyperpigmentation in sun-exposed areas	Yes	Yes
Sunlight-induced skin cancer	Yes – 13 yr	Yes – 13 yr
Sunlight-induced tongue tumor	Yes	No
Eyes		
Photophobia	Yes	Yes
Corneal opacity with neovascularization	Yes	Yes
Lower lid ectropion	Yes	No
Impaired vision	Yes	Yes
Nervous System		
Developmental delay/neurologic disease	No	No
Disease mechanism		
DNA repair defect	Yes – XPC	Yes – XPC